Noveko Receives the Green Light to Market its New Antimicrobial Respirator
Model in Europe
The Noveko(TM) RD2 respirators obtain FFP2 classification
EKO / TSX
MONTREAL, July 28 /CNW Telbec/ - Noveko International Inc. ("the Company") is pleased to announce that its subsidiary Noveko Inc. ("Noveko") has obtained FFP2 classification for its new model of antimicrobial respirators and can now bring them to market in all countries throughout the European Union. These respirators will be marketed as Noveko(TM) RD2 antimicrobial respirators.
The grant of this regulatory certification confirms that the Noveko(TM) RD2 antimicrobial respirators, which are considered personal protective equipment (PPE) pursuant to European Directive 89/686/EEC, respect the Directive's various health, safety and protection requirements, and have been designed and tested in compliance with the EN 149:2001+A1:2009 standard.
"We are very pleased with this additional recognition of the effectiveness and protection provided by our antimicrobial respirators. This certification not only gives us access to all countries in the European Union, but it will also facilitate the marketing of our respirators in several other territories that recognize these European standards," indicated Alain Bolduc, President and Chief Operating Officer of the Company.
The Company also points out that the necessary steps are continuing towards obtaining NIOSH certification in order to market its respirators in the United States.
Profile
Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technology, mainly air filters, surgical masks and respirators, as well as other products with antibacterial properties such as hand sanitizers - and the development, manufacturing and marketing of medical equipment, primarily portable real-time ultrasound scanners for use in human and veterinary medicine.
Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. Unless otherwise required under securities laws, the Company does not intend and undertakes no obligation to update or revise the forward-looking statements to account for new information, new events or new circumstances.
For further information: Chantal Vennat, Director, Investor Relations and Corporate Communications, Noveko International Inc., Tel: (514) 875-0606; http://www.noveko.com
Share this article